SCHEMBL15814062

SCHEMBL15814062

COC(=O)c1cc(OC(C)C)cc(C(=O)OC)c1CBr

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.44
▸ ULK1 O75385 1/20 0.43
▸ LMNA P02545 1/20 0.39
▸ KDM4E B2RXH2 5/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ PRMT5 O14744 1/20 0.35
▸ WDR77 Q9BQA1 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ TSHR P16473 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ CA12 O43570 2/20 0.34
▸ CA1 P00915 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5838605 0.83 KDM4E (0.47) ALDH1A1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL15830707 0.80 LMNA (0.45) ALDH1A1ULK1LMNAKDM4ECYP1A2
SCHEMBL15814064 0.80 ALDH1A1 (0.48) ALDH1A1LMNAKDM4ECYP2C9CYP2C19
SCHEMBL15813927 0.80 ALDH1A1 (0.49) ALDH1A1ULK1LMNAKDM4ECYP1A2
SCHEMBL30164066 0.79 ALDH1A1 (0.50) ALDH1A1ULK1LMNAKDM4ECYP1A2
SCHEMBL21200565 0.75 EPHX2 (0.43) ALDH1A1LMNAKDM4EMAPTKMT2A
SCHEMBL1791406 0.74 ALDH1A1 (0.56) ALDH1A1ULK1LMNAKDM4ECYP1A2
SCHEMBL1316757 0.73 CA12 (0.61) ALDH1A1LMNAKDM4ECYP1A2CYP2D6
SCHEMBL28365855 0.73 ALDH1A1 (0.54) ALDH1A1ULK1LMNAKDM4ECYP1A2
SCHEMBL15154385 0.73 HPGD (0.36) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3339303-B9 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2021-07-21 — — EP disclosed
EP-3339303-B9 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2021-07-21 — — EP disclosed
EP-3339303-B1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2020-06-24 — — EP disclosed
EP-3339303-B1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2020-06-24 — — EP disclosed
US-10246433-B2 Aryl and heteroaryl fused lactams PFIZER INC. (US) 2019-04-02 — — US disclosed
EP-3339303-A1 ARYL AND HETEROARYL FUSED LACTAMS Pfizer Inc (US) 2018-06-27 — — EP disclosed
EP-3339303-A1 ARYL AND HETEROARYL FUSED LACTAMS Pfizer Inc (US) 2018-06-27 — — EP disclosed
EP-2935238-B1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2017-12-27 — — EP disclosed
EP-2935238-B1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2017-12-27 — — EP disclosed
US-20170233368-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2017-08-17 — — US disclosed
US-20150175572-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2015-06-25 — — US disclosed
US-20150175572-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2015-06-25 — — US disclosed
US-9040515-B2 Aryl and heteroaryl fused lactams PFIZER INC. (US) 2015-05-26 — — US disclosed
US-9040515-B2 Aryl and heteroaryl fused lactams PFIZER INC. (US) 2015-05-26 — — US disclosed
US-9040515-B2 Aryl and heteroaryl fused lactams PFIZER INC. (US) 2015-05-26 — — US disclosed
WO-2014097041-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2014-06-26 — — WO disclosed
US-20140179667-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2014-06-26 — — US disclosed
WO-2014097041-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2014-06-26 — — WO disclosed
US-20140179667-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2014-06-26 — — US disclosed
US-20140179667-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2014-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179667-A1 ARYL AND HETEROARYL FUSED LACTAMS CCNY, MLX, NFXL1 ALDH1A1 2245/4885ULK1 3034/4885LMNA 1563/4885
US-20170233368-A1 ARYL AND HETEROARYL FUSED LACTAMS CCNY, MLX, NFXL1 ALDH1A1 2245/4885ULK1 3034/4885LMNA 1563/4885
US-20150175572-A1 ARYL AND HETEROARYL FUSED LACTAMS CCNY, MLX, NFXL1 ALDH1A1 2245/4885ULK1 3034/4885LMNA 1563/4885
US-10246433-B2 Aryl and heteroaryl fused lactams CCNY, MLX, NFXL1 ALDH1A1 2245/4885ULK1 3034/4885LMNA 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback